Summary proceedings from the bronchopulmonary dysplasia group

Area of Science:

• Neonatology
• Pulmonology
• Clinical Trial Design

Background:

• Bronchopulmonary dysplasia (BPD) affects approximately one-third of very low birth weight infants (<1000 g), causing significant short- and long-term morbidity, including chronic lung disease, language delay, cerebral palsy, and cognitive impairments.
• Existing knowledge gaps in BPD prevention and treatment hinder the development of effective clinical trials, necessitating a structured approach to research.
• The pulmonary group identified critical needs for BPD clinical trials: defining stages, clarifying definitions, and identifying patient subtypes to improve trial design and outcomes.

Framework:

• The study proposes a BPD clinical trials framework tailored to different disease stages: prevention, evolving BPD, and established BPD.
• This framework prioritizes drug-class evaluation based on BPD stage and severity (mild, moderate, severe).
• It emphasizes the need for clear BPD definitions and patient stratification to enhance trial efficacy.

Implementation:

• The research identifies gaps in basic science and pharmacologic knowledge crucial for designing effective BPD clinical trials.
• A list of potential drugs for BPD trials is provided, with priorities for evaluation based on disease stage.
• The proposed framework aims to guide the design of future clinical trials in neonates with BPD.

Implications:

• Implementing this framework can lead to more targeted and effective clinical trials for BPD.
• Improved trial design has the potential to reduce BPD incidence and severity, mitigating its long-term sequelae in preterm infants.
• Addressing knowledge gaps and prioritizing research areas will advance the field of neonatal respiratory medicine.